Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma
- VernacularTitle:肝细胞癌仑伐替尼耐药的分子机制
- Author:
Xiaomeng YAO
1
;
Keke SUN
1
;
Yunkai LIN
2
;
Hui WANG
1
;
Liwei DONG
2
;
Lei CHEN
2
;
Heping HU
1
Author Information
- Publication Type:Review
- Keywords: Carcinoma， Hepatocellular; Lenvatinib; Drug Resistance， Neoplasm
- From: Journal of Clinical Hepatology 2024;40(12):2524-2530
- CountryChina
- Language:Chinese
- Abstract: Hepatocellular carcinoma is the most common malignancy of the liver and poses serious health burdens on China and the whole world. However， most patients with hepatocellular carcinoma are already in the advanced stage at the time of diagnosis， with fewer opportunities for surgery and limited treatment options. In recent years， the advances in molecular targeted therapies have brought new hope for patients with advanced hepatocellular carcinoma. Among these therapies， lenvatinib is the second first-line drug after sorafenib approved by the US Food and Drug Administration for the treatment of advanced hepatocellular carcinoma， and it has attracted widespread attention for its powerful anti-tumor properties. However， the efficacy of lenvatinib is severely limited by its drug resistance. This article reviews the research advances in the molecular mechanisms of lenvatinib resistance in hepatocellular carcinoma and discusses possible ways to improve the efficacy of lenvatinib， so as to improve its efficacy.
